Pemetrexed for advanced stage nonsquamous non-small cell lung cancer: Latest evidence about its extended use and outcomes

Therapeutic Advances in Medical Oncology

Volumn 8, Issue 3, 2016, Pages 198-208

  Tomasini, Pascale ^a   Barlesi, Fabrice ^a   Mascaux, Celine ^a   Greillier, Laurent ^a  

^a AIX MARSEILLE UNIVERSITY   (France)

Author keywords

lung cancer; nonsquamous; pemetrexed; survival; tolerability

Indexed keywords

BIOLOGICAL MARKER; PEMETREXED; THYMIDYLATE SYNTHASE;

ADVANCED CANCER; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; GENE EXPRESSION; HUMAN; MAINTENANCE THERAPY; MONOTHERAPY; NON SMALL CELL LUNG CANCER; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PREDICTIVE VALUE; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME;

EID: 84968731701     PISSN: 17588340     EISSN: 17588359     Source Type: Journal    
DOI: 10.1177/1758834016644155     Document Type: Review

References (69)

1. Adjei A., Mandrekar S., Dy G., Molina J., Adjei A., Gandara D., et al.(2010) Phase II trial of pemetrexed plus bevacizumab for second-line therapy of patients with advanced non-small-cell lung cancer: NCCTG and SWOG study N0426. J Clin Oncol 28: 614-619.
2. Ardizzoni A., Tiseo M., Boni L., Vincent A., Passalacqua R., Buti S., et al.(2012) Pemetrexed versus pemetrexed and carboplatin as second-line chemotherapy in advanced non-small-cell lung cancer: results of the GOIRC 02-2006 randomized phase II study and pooled analysis with the NVALT7 trial. J Clin Oncol 30: 4501-4507.
3. Barlesi F., Scherpereel A., Gorbunova V., Gervais R., Vikström A., Chouaid C., et al.(2014) Maintenance bevacizumab-pemetrexed after first-line cisplatin-pemetrexed-bevacizumab for advanced nonsquamous nonsmall-cell lung cancer: updated survival analysis of the AVAPERL (MO22089) randomized phase III trial. Ann Oncol 25: 1044-1052.
4. Barlesi F., Scherpereel A., Rittmeyer A., Pazzola A., Ferrer Tur N., Kim J., et al.(2013) Randomized phase III trial of maintenance bevacizumab with or without pemetrexed after first-line induction with bevacizumab, cisplatin, and pemetrexed in advanced nonsquamous non-small-cell lung cancer: AVAPERL (MO22089). J Clin Oncol 31: 3004-3011.
5. Belani C., Brodowicz T., Ciuleanu T., Krzakowski M., Yang S., Franke F., et al.(2012) Quality of life in patients with advanced non-small-cell lung cancer given maintenance treatment with pemetrexed versus placebo (H3E-MC-JMEN): results from a randomised, double-blind, phase III study. Lancet Oncol 13: 292-299.
6. Belani C., Yamamoto N., Bondarenko I., Poltoratskiy A., Novello S., Tang J., et al.(2014) Randomized phase II study of pemetrexed/cisplatin with or without axitinib for non-squamous non-small-cell lung cancer. BMC Cancer 14: 290.
7. Bylicki O., Ferlay C., Chouaid C., Lavolé A., Barlési F., Dubos C., et al.(2013) Efficacy of pemetrexed as second-line therapy in advanced NSCLC after either treatment-free interval or maintenance therapy with gemcitabine or erlotinib in IFCT-GFPC 05-02 phase III study. J Thorac Oncol 8: 906-914.
8. Casey E., Harb W., Bradford D., Bufill J., Nattam S., Patel J., et al.(2010) Randomized, double-blinded, multicenter, phase II study of pemetrexed, carboplatin, and bevacizumab with enzastaurin or placebo in chemonaïve patients with stage IIIB/IV non-small cell lung cancer: Hoosier Oncology Group LUN06-116. J Thorac Oncol 5: 1815-1820.
9. Chamizo C., Zazo S., Dómine M., Cristóbal I., García-Foncillas J., Rojo F., et al.(2015) Thymidylate synthase expression as a predictive biomarker of pemetrexed sensitivity in advanced non-small cell lung cancer. BMC Pulm Med 15: 132.
10. Chen H., Modiano M., Neal J., Brahmer J., Rigas J., Jotte R., et al.(2014) A phase II multicentre study of ziv-aflibercept in combination with cisplatin and pemetrexed in patients with previously untreated advanced/metastatic non-squamous non-small cell lung cancer. Br J Cancer 110: 602-608.
11. Chiappori A., Bepler G., Barlesi F., Soria J., Reck M., Bearz A., et al.(2010) Phase II, double-blinded, randomized study of enzastaurin plus pemetrexed as second-line therapy in patients with advanced non-small cell lung cancer. J Thorac Oncol 5: 369-375.
12. Clarke S., Boyer M., Millward M., Underhill C., Moylan E., Yip D., et al.(2005) A phase I/II study of pemetrexed and vinorelbine in patients with non-small cell lung cancer. Lung Cancer 49: 401-412.
13. Cullen M., Zatloukal P., Sörenson S., Novello S., Fischer J., Joy A., et al.(2008) A randomized phase III trial comparing standard and high-dose pemetrexed as second-line treatment in patients with locally advanced or metastatic non-small-cell lung cancer. Ann Oncol 19: 939-945.
14. De Boer R., Arrieta Ó., Yang C., Gottfried M., Chan V., Raats J., et al.(2011) Vandetanib plus pemetrexed for the second-line treatment of advanced non-small-cell lung cancer: a randomized, double-blind phase III trial. J Clin Oncol 29: 1067-1074.
15. Dittrich C., Papai-Szekely Z., Vinolas N., Sederholm C., Hartmann J., Behringer D., et al.(2014) A randomised phase II study of pemetrexed versus pemetrexed+erlotinib as second-line treatment for locally advanced or metastatic non-squamous non-small cell lung cancer. Eur J Cancer 50: 1571-1580.
16. Doebele R., Spigel D., Tehfe M., Thomas S., Reck M., Verma S., et al.(2015) Phase II, randomized, open-label study of ramucirumab in combination with first-line pemetrexed and platinum chemotherapy in patients with nonsquamous, advanced/metastatic non-small cell lung cancer. Cancer 121: 883-892.
17. Dy G., Molina J., Qi Y., Ansari R., Thomas S., Ross H., et al.(2014) NCCTG N0821 (Alliance): A phase II first-line study of pemetrexed, carboplatin, and bevacizumab in elderly patients with advanced nonsquamous non-small-cell lung cancer with good performance status. J Thorac Oncol 9: 1146-1153.
18. Edelman M., Otterson G., Leach J., Malpass T., Salgia R., Jones D., et al.(2011) Multicenter phase II trial of Motexafin gadolinium and pemetrexed for second-line treatment in patients with non-small cell lung cancer. J Thorac Oncol 6: 786-789.
19. Ellis P., Kaiser R., Zhao Y., Stopfer P., Gyorffy S., Hanna N., (2010) Phase I open-label study of continuous treatment with BIBF 1120, a triple angiokinase inhibitor, and pemetrexed in pretreated non-small cell lung cancer patients. Clin Cancer Res 16: 2881-2889.
20. Fennell D., Myrand S., Nguyen T., Ferry D., Kerr K., Maxwell P., et al.(2014) Association between gene expression profiles and clinical outcome of pemetrexed-based treatment in patients with advanced non-squamous non-small cell lung cancer: exploratory results from a phase II study. PloS One 9: e107455.
21. Gervais R., Robinet G., Clément-Duchêne C., Denis F., El Kouri C., Martin P., et al.(2013) Pemetrexed and carboplatin, an active option in first-line treatment of elderly patients with advanced non-small cell lung cancer (NSCLC): a phase II trial. Lung Cancer 80: 185-190.
22. Grønberg B., Bremnes R., Fløtten O., Amundsen T., Brunsvig P., Hjelde H., et al.(2009) Phase III study by the Norwegian lung cancer study group: pemetrexed plus carboplatin compared with gemcitabine plus carboplatin as first-line chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 27: 3217-3224.
23. Grønberg B., Lund-Iversen M., Strøm E., Brustugun O., Scott H., (2013) Associations between TS, TTF-1, FR-α FPGS, and overall survival in patients with advanced non-small-cell lung cancer receiving pemetrexed plus carboplatin or gemcitabine plus carboplatin as first-line chemotherapy. J Thorac Oncol 8: 1255-1264.
24. Hanna N., Shepherd F., Fossella F., Pereira J., De Marinis F., von Pawel J., et al.(2004) Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 22: 1589-1597.
25. Heist R., Wang X., Hodgson L., Otterson G., Stinchcombe T., Gandhi L., et al.(2014) CALGB 30704 (Alliance): A randomized phase II study to assess the efficacy of pemetrexed or sunitinib or pemetrexed plus sunitinib in the second-line treatment of advanced non-small-cell lung cancer. J Thorac Oncol 9: 214-221.
26. Jalal S., Waterhouse D., Edelman M. J., Nattam S., Ansari R., Koneru K., et al. (2009) Pemetrexed plus cetuximab in patients with recurrent non-small cell lung cancer (NSCLC): a phase I/II study from the Hoosier oncology group. J Thorac Oncol 4: 1420-1424.
27. Karampeazis A., Voutsina A., Souglakos J., Kentepozidis N., Giassas S., Christofillakis C., et al.(2013) Pemetrexed versus erlotinib in pretreated patients with advanced non-small cell lung cancer: a Hellenic Oncology Research Group (HORG) randomized phase III study. Cancer 119: 2754-2764.
28. Kim Y., Hirabayashi M., Kosaka S., Nikaidoh J., Yamamoto Y., Shimada M., et al.(2013) Phase II study of pemetrexed as first-line treatment in elderly (≥75) non-squamous non-small-cell lung cancer: Kyoto Thoracic Oncology Research Group Trial 0901. Cancer Chemother Pharmacol 71: 1445-1451.
29. Krawczyk P., Kucharczyk T., Kowalski D., Powrózek T., Ramlau R., Kalinka-Warzocha E., et al.(2014) Polymorphisms in TS, MTHFR and ERCC1 genes as predictive markers in first-line platinum and pemetrexed therapy in NSCLC patients. J Cancer Res Clin Oncol 140: 2047-2057.
30. Kumar G., Woods B., Hess L., Treat J., Boye M., Bryden P., et al.(2015) Cost-effectiveness of first-line induction and maintenance treatment sequences in non-squamous non-small cell lung cancer (NSCLC) in the U.S. Lung Cancer 89: 294-300.
31. Lee S., Noh K., Lee J., Lee E., Min K., Hur G., et al.(2013) Thymidylate synthase and ERCC1 as predictive markers in patients with pulmonary adenocarcinoma treated with pemetrexed and cisplatin. Lung Cancer 81: 102-108.
32. Masters G., Temin S., Azzoli C., Giaccone G., Baker S., Brahmer J., et al.(2015) Systemic therapy for stage IV non-small-cell lung cancer: American society of clinical oncology clinical practice guideline update. J Clin Oncol 33: 3488-3515.
33. McDonald A., Vasey P., Adams L., Walling J., Woodworth J., Abrahams T., et al.(1998) A phase I and pharmacokinetic study of LY231514, the multitargeted antifolate. Clin Cancer Res 4: 605-610.
34. McLeod H., Cassidy J., Powrie R., Priest D., Zorbas M., Synold T., et al.(2000) Pharmacokinetic and pharmacodynamic evaluation of the glycinamide ribonucleotide formyltransferase inhibitor AG2034. Clin Cancer Res 6: 2677-2684.
35. Minami S., Kijima T., Hamaguchi M., Nakatani T., Koba T., Takahashi R., et al.(2013) Phase II study of pemetrexed plus intermittent erlotinib combination therapy for pretreated advanced non-squamous non-small cell lung cancer with documentation of epidermal growth factor receptor mutation status. Lung Cancer 82: 271-275.
36. Mita A., Hammond L., Bonate P., Weiss G., McCreery H., Syed S., et al.(2006) Phase I and pharmacokinetic study of tasidotin hydrochloride (ILX651), a third-generation dolastatin-15 analogue, administered weekly for 3 weeks every 28 days in patients with advanced solid tumors. Clin Cancer Res 12: 5207-5215.
37. Mubarak N., Gaafar R., Shehata S., Hashem T., Abigeres D., Azim H., et al.(2012) A randomized, phase II study comparing pemetrexed plus best supportive care versus best supportive care as maintenance therapy after first-line treatment with pemetrexed and cisplatin for advanced, non-squamous, non-small cell lung cancer. BMC Cancer 12: 423.
38. Niyikiza C., Baker S., Seitz D., Walling J., Nelson K., Rusthoven J., et al.(2002) Homocysteine and methylmalonic acid: markers to predict and avoid toxicity from pemetrexed therapy. Mol Cancer Ther 1: 545-552.
39. Ortuzar W., Hanna N., Pennella E., Peng G., Langer C., Monberg M., et al.(2012) Brain metastases as the primary site of relapse in two randomized phase III pemetrexed trials in advanced non-small-cell lung cancer. Clin Lung Cancer 13: 24-30.
40. Patel J., Hensing T., Rademaker A., Hart E., Blum M., Milton D., et al.(2009) Phase II study of pemetrexed and carboplatin plus bevacizumab with maintenance pemetrexed and bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer. J Clin Oncol 27: 3284-3289.
41. Patel J., Socinski M., Garon E., Reynolds C., Spigel D., Olsen M., et al.(2013) PointBreak: a randomized phase III study of pemetrexed plus carboplatin and bevacizumab followed by maintenance pemetrexed and bevacizumab versus paclitaxel plus carboplatin and bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancer. J Clin Oncol 31: 4349-4357.
42. Paz-Ares L., de Marinis F., Dediu M., Thomas M., Pujol J., Bidoli P., et al.(2012) Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase III, randomised controlled trial. Lancet Oncol 13: 247-255.
43. Paz-Ares L., de Marinis F., Dediu M., Thomas M., Pujol J., Bidoli P., et al.(2013) PARAMOUNT: Final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer. J Clin Oncol 31: 2895-2902.
44. Paz-Ares L., Mezger J., Ciuleanu T., Fischer J., von Pawel J., Provencio M., et al.(2015) Necitumumab plus pemetrexed and cisplatin as first-line therapy in patients with stage IV non-squamous non-small-cell lung cancer (INSPIRE): an open-label, randomised, controlled phase III study. Lancet Oncol 16: 328-337.
45. Pujol J., Paul S., Chouaki N., Peterson P., Moore P., Berry D., et al.(2007) Survival without common toxicity criteria grade 3/4 toxicity for pemetrexed compared with docetaxel in previously treated patients with advanced non-small cell lung cancer (NSCLC): a risk-benefit analysis. J Thorac Oncol 2: 397-401.
46. Ramlau R., Thomas M., Novello S., Plummer R., Reck M., Kaneko T., et al.(2015) Phase I study of lapatinib and pemetrexed in the second-line treatment of advanced or metastatic non-small-cell lung cancer with assessment of circulating cell free thymidylate synthase RNA as a potential biomarker. Clin Lung Cancer 16: 348-357.
47. Rittmeyer A., Gorbunova V., Vikström A., Scherpereel A., Kim J., Ahn M., et al.(2013) Health-related quality of life in patients with advanced nonsquamous non-small-cell lung cancer receiving bevacizumab or bevacizumab-plus-pemetrexed maintenance therapy in AVAPERL (MO22089). J Thorac Oncol 8: 1409-1416.
48. Rudin C., Brahmer J., Juergens R., Hann C., Ettinger D., Sebree R., et al.(2013) Phase II study of pemetrexed and itraconazole as second-line therapy for metastatic nonsquamous non-small-cell lung cancer. J Thorac Oncol 8: 619-623.
49. Scagliotti G., Felip E., Besse B., von Pawel J., Mellemgaard A., Reck M., et al.(2013) An open-label, multicenter, randomized, phase II study of pazopanib in combination with pemetrexed in first-line treatment of patients with advanced-stage non-small-cell lung cancer. J Thorac Oncol 8: 1529-1537.
50. Scagliotti G., Germonpré P., Bosquée L., Vansteenkiste J., Gervais R., Planchard D., et al.(2010) A randomized phase II study of bortezomib and pemetrexed, in combination or alone, in patients with previously treated advanced non-small-cell lung cancer. Lung Cancer 68: 420-426.
51. Scagliotti G., Parikh P., von Pawel J., Biesma B., Vansteenkiste J., Manegold C., et al.(2008) Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 26: 3543-3551.
52. Scagliotti G., Park K., Patil S., Rolski J., Goksel T., Martins R., et al.(2009) Survival without toxicity for cisplatin plus pemetrexed versus cisplatin plus gemcitabine in chemonaïve patients with advanced non-small cell lung cancer: a risk-benefit analysis of a large phase III study. Eur J Cancer 45: 2298-2303.
53. Schiller J. H., von Pawel J., Schütt P., Ansari R. H., Thomas M., Saleh M., et al. (2010) Pemetrexed with or without matuzumab as second-line treatment for patients with stage IIIB/IV non-small cell lung cancer. J Thorac Oncol 5: 1977-1985.
54. Schmid-Bindert G., Gebbia V., Mayer F., Arriola E., Márquez-Medina D., Syrigos K., et al.(2013) Phase II study of pemetrexed and cisplatin plus cetuximab followed by pemetrexed and cetuximab maintenance therapy in patients with advanced nonsquamous non-small cell lung cancer. Lung Cancer 81: 428-434.
55. Schuette W., Gröschel A., Sebastian M., Andreas S., Müller T., Schneller F., et al.(2013) A randomized phase II study of pemetrexed in combination with cisplatin or carboplatin as first-line therapy for patients with locally advanced or metastatic non-small-cell lung cancer. Clin Lung Cancer 14: 215-223.
56. Shaw A., Varghese A., Solomon B., Costa D., Novello S., Mino-Kenudson M., et al.(2013) Pemetrexed-based chemotherapy in patients with advanced, ALK-positive non-small cell lung cancer. Ann Oncol 24: 59-66.
57. Spigel D., Hainsworth J., Barton J., Patton J., Zubkus J., Simons L., et al.(2010) Phase II study of biweekly pemetrexed and gemcitabine in patients with previously untreated advanced non-small cell lung cancer. J Thorac Oncol 5: 841-845.
58. Spigel D., Hainsworth J., Shipley D., Ervin T., Kohler P., Lubiner E., et al.(2012) A randomized phase II trial of pemetrexed/gemcitabine/bevacizumab or pemetrexed/carboplatin/bevacizumab in the first-line treatment of elderly patients with advanced non-small cell lung cancer. J Thorac Oncol 7: 196-202.
59. Stathopoulos G., Dimitroulis J., Toubis M., Katis C., Karaindros D., Stathopoulos J., et al.(2007) Pemetrexed combined with paclitaxel in patients with advanced or metastatic non-small-cell lung cancer: a phase I-II trial. Lung Cancer 57: 66-71.
60. Sun J., Ahn J., Jung S., Sun J., Ha S., Han J., et al.(2015) Pemetrexed plus cisplatin versus gemcitabine plus cisplatin according to thymidylate synthase expression in nonsquamous non-small-cell lung cancer: a biomarker-stratified randomized phase II trial. J Clin Oncol 33: 2450-2456.
61. Syrigos K., Vansteenkiste J., Parikh P., von Pawel J., Manegold C., Martins R., et al.(2010) Prognostic and predictive factors in a randomized phase III trial comparing cisplatin-pemetrexed versus cisplatin-gemcitabine in advanced non-small-cell lung cancer. Ann Oncol 21: 556-561.
62. Torre L., Bray F., Siegel R., Ferlay J., Lortet-Tieulent J., Jemal A., (2015) Global cancer statistics, 2012. CA A Cancer J Clin 65: 87-108.
63. Treat J., Scagliotti G., Peng G., Monberg M., Obasaju C., Socinski M., (2012) Comparison of pemetrexed plus cisplatin with other first-line doublets in advanced non-small cell lung cancer (NSCLC): a combined analysis of three phase III trials. Lung Cancer 76: 222-227.
64. Waller C., Vynnychenko I., Bondarenko I., Shparyk Y., Hodge J., Freeman A., et al.(2015) An open-label, multicenter, randomized phase Ib/II study of eribulin mesylate administered in combination with pemetrexed versus pemetrexed alone as second-line therapy in patients with advanced nonsquamous non-small-cell lung cancer. Clin Lung Cancer 16: 92-99.
65. Xu C., Wang G., Wang W., Gao W., Han C., Gao J., et al.(2015) Association between EML4-ALK fusion gene and thymidylate synthase mRNA expression in non-small cell lung cancer tissues. Exp Ther Med 9: 2151-2154.
66. Zhou Q., Cheng Y., Yang J., Zhao M., Zhang L., Zhang X., et al.(2014) Pemetrexed versus gefitinib as a second-line treatment in advanced nonsquamous nonsmall-cell lung cancer patients harboring wild-type EGFR (CTONG0806): a multicenter randomized trial. Ann Oncol 25: 2385-2391.
67. Zinner R., Fossella F., Gladish G., Glisson B., Blumenschein G., Papadimitrakopoulou V., et al.(2005) Phase II study of pemetrexed in combination with carboplatin in the first-line treatment of advanced nonsmall cell lung cancer. Cancer 104: 2449-2456.
68. Zinner R., Novello S., Peng G., Herbst R., Obasaju C., Scagliotti G., (2010) Comparison of patient outcomes according to histology among pemetrexed-treated patients with stage IIIB/IV non-small-cell lung cancer in two phase II trials. Clin Lung Cancer 11: 126-131.
69. Zukin M., Barrios C., Pereira J., Ribeiro R., Beato C., de M., do Nascimento Y., et al.(2013) Randomized phase III trial of single-agent pemetrexed versus carboplatin and pemetrexed in patients with advanced non-small-cell lung cancer and Eastern Cooperative Oncology Group performance status of 2. J Clin Oncol 31: 2849-2853.